Safety, efficacy and biomarkers analysis of mesenchymal stromal cells therapy in ARDS: a systematic review and meta-analysis based on phase I and II RCTs

Table 1 PICOS criteria and Cochrane Risk of bias in included Trails

Population	Interventions	Comparators	Outcomes	Study types
PICOS criteria
Patients with Berlin criteria-defined ARDS, Age > 18 years, not animals	MSCs/MSC, Progenitor cell, mesenchymal stem cell, mesenchymal stromal cell, stem cell	Placebo	Subjects with Adverse events (AEs), subjects with Serious Adverse events (SAEs), mortality, PaO₂/FiO₂, Biomarkers	randomized controlled trials (RCT), blind or not

Trails	Randomization method	Allocation concealment	Blinding		Incomplete outcome data	Selective reporting	Other bias
Trails	Randomization method	Allocation concealment	Participants and personnel	Assessment	Incomplete outcome data	Selective reporting	Other bias
Cochrane Risk of bias in included Trails
Monsel et al. [22]	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk
Bellingan et al. [21]	Low risk	Low risk	Unclear risk	Unclear risk	Low risk	Low risk	High risk
Lanzoni et al. [20]	Low risk	Unclear risk	Unclear risk	Unclear risk	Low risk	Low risk	Low risk
Matthay et al. [19]	Low risk	Low risk	Unclear risk	Unclear risk	Low risk	Low risk	High risk
Zheng et al. [18]	Unclear risk	Unclear risk	Unclear risk	Unclear risk	Low risk	Low risk	Low risk

ISSN: 1757-6512